Intech Biopharm Corporation

Taipei Exchange 6461.TWO

Intech Biopharm Corporation EBIT Margin for the year ending December 31, 2023: -1,177.68%

Intech Biopharm Corporation EBIT Margin is -1,177.68% for the year ending December 31, 2023, a 8.64% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Intech Biopharm Corporation EBIT Margin for the year ending December 31, 2022 was -1,289.11%, a -77.38% change year over year.
  • Intech Biopharm Corporation EBIT Margin for the year ending December 31, 2021 was -726.75%, a 34.33% change year over year.
  • Intech Biopharm Corporation EBIT Margin for the year ending December 31, 2020 was -1,106.60%.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Taipei Exchange: 6461.TWO

Intech Biopharm Corporation

CEO Mr. Wei-Shiu Wu
IPO Date July 15, 2014
Location
Headquarters No. 36, Ruiguang Road
Employees 82
Sector Health Care
Industries
Pharmaceuticals
Description

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email